Maryam Saeidifar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maryam Saeidifar has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
Ali Akbar Saboury
10 shared publicationsHassan Mansouri-Torshizi
9 shared publicationsAdeleh Divsalar
C Faculty of Biological Sciences, Department of Cell and Molecular Biology , Kharazmi University , Tehran , Iran
3 shared publicationsKhatereh Abdi
3 shared publications- Mona Shahlaei
Department of Nanotechnology and Advanced Materials Materials and Energy Research Centre Karaj Iran
3 shared publications Ali Khanlarkhani
Department of Nanotechnology and Advanced Materials Materials and Energy Research Center Karaj Iran
2 shared publications
Latest Publications
- 24 March 2025
- Published by Wiley in Applied Organometallic Chemistry
- Vol. 39 (4)
A New Trend to Introduce a Biocompatible Drug Carrier Based on Immunoglobulin for Prolonged Release of Palladium (II) Complex as an Anticancer Agent: Drug Release and Cytotoxicity Assessment
Severe side effects and low chemotherapy efficacy remain challenges in cancer treatment. Therefore, this research is aimed at investigating a colloidal drug nanocarrier based on immunoglobulin nanoparticles (IgGNPs) for sustained release of an anticancer agent. A novel palladium (II) complex (PBD) loaded to IgGNPs and its formation (PBD@IgGNP) was characterized by FTIR, DLS, and AFM techniques. The size of designed system was 797 ± 121 nm, with a particle size distribution and surface charge greater than those of IgGNP indicating the conjugation of PBD and IgGNP. The release behavior indicated that 33.66% of PBD and 12.76% of encapsulated PBD in IgGNP were released at 579 h, while carboplatin was completely released at 216 h. The release mechanism followed Korsmeyer–Peppas model and non‐Fickian law. Other kinetic parameters of the release are also presented. Furthermore, MTT assay showed that IC50 values of PBD and PBD@IgGNP on breast cancer cells, 4T1, were 0.75 mM while 78% of the cells were viable at the same concentration of carboplatin. DAPI, AO/EB, and PCR staining indicated that the apoptotic induction of PBD@IgGNP was greater than PBD. Moreover, in vivo results confirmed the apoptotic induction and inhibition of tumor growth in the presence of PBD@IgGNP. These valuable achievements proposed a potential nanocarrier to increase the apoptotic induction and effectiveness of anticancer drugs and decrease their side effects.
- 24 March 2025
- Published by Wiley in Applied Organometallic Chemistry
- Vol. 39 (4)
A New Trend to Introduce a Biocompatible Drug Carrier Based on Immunoglobulin for Prolonged Release of Palladium (II) Complex as an Anticancer Agent: Drug Release and Cytotoxicity Assessment
Severe side effects and low chemotherapy efficacy remain challenges in cancer treatment. Therefore, this research is aimed at investigating a colloidal drug nanocarrier based on immunoglobulin nanoparticles (IgGNPs) for sustained release of an anticancer agent. A novel palladium (II) complex (PBD) loaded to IgGNPs and its formation (PBD@IgGNP) was characterized by FTIR, DLS, and AFM techniques. The size of designed system was 797 ± 121 nm, with a particle size distribution and surface charge greater than those of IgGNP indicating the conjugation of PBD and IgGNP. The release behavior indicated that 33.66% of PBD and 12.76% of encapsulated PBD in IgGNP were released at 579 h, while carboplatin was completely released at 216 h. The release mechanism followed Korsmeyer–Peppas model and non‐Fickian law. Other kinetic parameters of the release are also presented. Furthermore, MTT assay showed that IC50 values of PBD and PBD@IgGNP on breast cancer cells, 4T1, were 0.75 mM while 78% of the cells were viable at the same concentration of carboplatin. DAPI, AO/EB, and PCR staining indicated that the apoptotic induction of PBD@IgGNP was greater than PBD. Moreover, in vivo results confirmed the apoptotic induction and inhibition of tumor growth in the presence of PBD@IgGNP. These valuable achievements proposed a potential nanocarrier to increase the apoptotic induction and effectiveness of anticancer drugs and decrease their side effects.
- 4 June 2024
- Published by Springer Nature in BioNanoScience
- Vol. 14 (3) , 3320-3329
Effect of the Presence of Colloidal Gamma Globulin Nanocarrier for Sustained Carboplatin Release Enhancement: Preparation, Characterization, Drug Release and Efficacy Assessment
- 4 June 2024
- Published by Springer Nature in BioNanoScience
- Vol. 14 (3) , 3320-3329
Effect of the Presence of Colloidal Gamma Globulin Nanocarrier for Sustained Carboplatin Release Enhancement: Preparation, Characterization, Drug Release and Efficacy Assessment
- 5 May 2024
- Published by Elsevier in Surfaces and Interfaces
- Vol. 49, 104429
Improvement of biomedical properties of PEO-treated titanium with flurbiprofen and exosome conjugation
- 5 May 2024
- Published by Elsevier in Surfaces and Interfaces
- Vol. 49, 104429
Improvement of biomedical properties of PEO-treated titanium with flurbiprofen and exosome conjugation
- 7 March 2024
- Published by Wiley in ChemistrySelect
- Vol. 9 (10)
A Novel Carrier Based on DNA and Exosome to Sustained Release of 5‐Fluorouracil Anticancer Drug
The development of effective drug delivery systems is crucial for improving cancer treatment outcomes. A promising carrier using a combination of DNA and exosomes (EXO) was synthesized to sustain the release of the powerful anticancer drug 5‐fluorouracil (5‐FU). The carrier was prepared by encapsulating 5‐FU‐loaded exosomes (5‐FU.EXO) in the heated DNA carriers (5‐FU.EXO@DNA). Alteration of the DNA structure was studied using molecular dynamics. The physicochemical properties of the carriers were characterized using fourier‐transform infrared spectroscopy (FTIR), field‐emission scanning electron microscopy (FESEM), and dynamic light scattering (DLS). The 5‐FU.EXO@DNA carrier exhibited good stability and biocompatibility, with a uniform size distribution (709±269 nm) and a zeta potential of +312 mV. The interaction between 5‐FU and DNA was confirmed using molecular docking. In vitro release studies showed that both 5‐FU@DNA and 5‐FU.EXO@DNA carriers achieved sustained release of 5‐FU for 576 h, with cumulative releases of approximately 83 % and 89 %, respectively. The 5‐FU release profile showed 40 % release over 86 h. The release rate and other kinetic parameters were also determined. Furthermore, the release kinetics followed by the Korsmeyer‐Peppas model and the diffusion mechanism plays a significant role in controlling the release process.
- 7 March 2024
- Published by Wiley in ChemistrySelect
- Vol. 9 (10)
A Novel Carrier Based on DNA and Exosome to Sustained Release of 5‐Fluorouracil Anticancer Drug
The development of effective drug delivery systems is crucial for improving cancer treatment outcomes. A promising carrier using a combination of DNA and exosomes (EXO) was synthesized to sustain the release of the powerful anticancer drug 5‐fluorouracil (5‐FU). The carrier was prepared by encapsulating 5‐FU‐loaded exosomes (5‐FU.EXO) in the heated DNA carriers (5‐FU.EXO@DNA). Alteration of the DNA structure was studied using molecular dynamics. The physicochemical properties of the carriers were characterized using fourier‐transform infrared spectroscopy (FTIR), field‐emission scanning electron microscopy (FESEM), and dynamic light scattering (DLS). The 5‐FU.EXO@DNA carrier exhibited good stability and biocompatibility, with a uniform size distribution (709±269 nm) and a zeta potential of +312 mV. The interaction between 5‐FU and DNA was confirmed using molecular docking. In vitro release studies showed that both 5‐FU@DNA and 5‐FU.EXO@DNA carriers achieved sustained release of 5‐FU for 576 h, with cumulative releases of approximately 83 % and 89 %, respectively. The 5‐FU release profile showed 40 % release over 86 h. The release rate and other kinetic parameters were also determined. Furthermore, the release kinetics followed by the Korsmeyer‐Peppas model and the diffusion mechanism plays a significant role in controlling the release process.
- 19 December 2023
- Published by Elsevier in Journal of Molecular Structure
- Vol. 1301
Platinum-based drugs in cancer treatment: Expanding horizons and overcoming resistance
- 19 December 2023
- Published by Elsevier in Journal of Molecular Structure
- Vol. 1301
Platinum-based drugs in cancer treatment: Expanding horizons and overcoming resistance
- 23 May 2023
- Published by Wiley in ChemistrySelect
- Vol. 8 (20)
Preparation and Characterization of 5‐Fluorouracil Loaded Cellulose and Exosome Nanocarriers: Sustained Release Behavior and Cytotoxicity Studies**
In recent years, much effort has been devoted to designing nanoparticle drug delivery systems and improving the efficacy of anticancer drugs. This study focused on the preparation of a novel biocompatible nanocarrier based on bacterial cellulose (BC) in the presence of exosome (Exo) for the controlled release of 5‐fluorouracil (5‐FU), known as 5‐FU.Exo@BC. The physicochemical properties of 5‐FU.Exo@BC were thoroughly characterized using field emission scanning electron microscopy (FESEM), differential scanning calorimetry (DSC), Fourier‐transform infrared spectroscopy (FTIR), and X‐ray diffraction (XRD). These results confirmed the successful preparation of 5‐FU.Exo@BC. The release behavior of 5‐FU.Exo@BC compared with 5‐FU and 5‐FU@BC demonstrated a significant sustained release over 162 h. The release mechanism of the above three systems followed Korsmeyer‐Peppas with non‐Fickian diffusion for 5‐FU@BC and 5‐FU.Exo@BC. Furthermore, the viability of HT‐29 cells (human colon cancer cell lines) against BC, 5‐FU@BC and 5‐FU.Exo@BC indicated that 5‐FU has promising efficacy in 5‐FU.Exo@BC system. Subsequently, the prepared bio‐nanocomposite could be suggested as a potential drug delivery system with an effective controlled‐release function.
- 23 May 2023
- Published by Wiley in ChemistrySelect
- Vol. 8 (20)
Preparation and Characterization of 5‐Fluorouracil Loaded Cellulose and Exosome Nanocarriers: Sustained Release Behavior and Cytotoxicity Studies**
In recent years, much effort has been devoted to designing nanoparticle drug delivery systems and improving the efficacy of anticancer drugs. This study focused on the preparation of a novel biocompatible nanocarrier based on bacterial cellulose (BC) in the presence of exosome (Exo) for the controlled release of 5‐fluorouracil (5‐FU), known as 5‐FU.Exo@BC. The physicochemical properties of 5‐FU.Exo@BC were thoroughly characterized using field emission scanning electron microscopy (FESEM), differential scanning calorimetry (DSC), Fourier‐transform infrared spectroscopy (FTIR), and X‐ray diffraction (XRD). These results confirmed the successful preparation of 5‐FU.Exo@BC. The release behavior of 5‐FU.Exo@BC compared with 5‐FU and 5‐FU@BC demonstrated a significant sustained release over 162 h. The release mechanism of the above three systems followed Korsmeyer‐Peppas with non‐Fickian diffusion for 5‐FU@BC and 5‐FU.Exo@BC. Furthermore, the viability of HT‐29 cells (human colon cancer cell lines) against BC, 5‐FU@BC and 5‐FU.Exo@BC indicated that 5‐FU has promising efficacy in 5‐FU.Exo@BC system. Subsequently, the prepared bio‐nanocomposite could be suggested as a potential drug delivery system with an effective controlled‐release function.
- 4 July 2022
- Published by Wiley in Journal of Biomedical Materials Research Part B: Applied Biomaterials
- Vol. 110 (12) , 2636-2648
Sustained release of sulforaphane by bioactive extracellular vesicles for neuroprotective effect on chick model
Novel studies have shown neurological treatment possibilities with extracellular vesicles (EVs) as natural particles with a special composition that are produced by different cell types. Their stability, natural structure, composition, and bioavailability make them good candidates as drug vehicles. Here, EVs were isolated from amniotic fluid (AF) through differential centrifugation, and characterized for size (R2 = 0.99) kinetic model by non‐Fickian diffusion case II (n = 0.44, passive loading) and Fickian diffusion case I (n = 0.41, active and active‐passive loading). SFN‐loaded EVs (SFN@EVs; 11 μM: 103 nM) stimulated hPC‐12 cell proliferation. The gene expression analysis revealed that SFN@EVs could upregulate Nrf2 and reduce IL‐6 expression. Eventually, histopathological results of the coronal cross‐section of the chick embryos brain showed treatment with SFN@EVs. This treatment illustrated normality in the gray and white matter and the orientation of the bipolar neurons. Our findings showed EVs' potentially acting as a gene expression regulator in autism spectrum disorder.
- 4 July 2022
- Published by Wiley in Journal of Biomedical Materials Research Part B: Applied Biomaterials
- Vol. 110 (12) , 2636-2648
Sustained release of sulforaphane by bioactive extracellular vesicles for neuroprotective effect on chick model
Novel studies have shown neurological treatment possibilities with extracellular vesicles (EVs) as natural particles with a special composition that are produced by different cell types. Their stability, natural structure, composition, and bioavailability make them good candidates as drug vehicles. Here, EVs were isolated from amniotic fluid (AF) through differential centrifugation, and characterized for size (R2 = 0.99) kinetic model by non‐Fickian diffusion case II (n = 0.44, passive loading) and Fickian diffusion case I (n = 0.41, active and active‐passive loading). SFN‐loaded EVs (SFN@EVs; 11 μM: 103 nM) stimulated hPC‐12 cell proliferation. The gene expression analysis revealed that SFN@EVs could upregulate Nrf2 and reduce IL‐6 expression. Eventually, histopathological results of the coronal cross‐section of the chick embryos brain showed treatment with SFN@EVs. This treatment illustrated normality in the gray and white matter and the orientation of the bipolar neurons. Our findings showed EVs' potentially acting as a gene expression regulator in autism spectrum disorder.